Alzamend Neuro Inc (ALZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 04/30
| 04-2022 | 01-2022 | 10-2021 | 07-2021 | 06-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 14,064 | 11,790 | 13,573 | 15,618 | N/A |
| Other current assets | 0 | 0 | 0 | 0 | 983 |
| TOTAL | $14,414 | $12,429 | $14,501 | $16,818 | $983 |
| Non-Current Assets | |||||
| PPE Net | 103 | N/A | N/A | N/A | N/A |
| TOTAL | $103 | $N/A | $N/A | $N/A | $N/A |
| Total Assets | $14,516 | $12,429 | $14,501 | $16,818 | $983 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | N/A | N/A | 345 | 340 | N/A |
| Accounts payable and accrued liabilities | 1,165 | 467 | 1,131 | 1,133 | 0 |
| Other current liabilities | N/A | N/A | N/A | N/A | 61 |
| TOTAL | $1,165 | $467 | $1,476 | $1,473 | $61 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $1,165 | $467 | $1,476 | $1,473 | $61 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 71 | 67 | 66 | 64 | N/A |
| Common Shares | 10 | 9 | 9 | 9 | N/A |
| Retained earnings | -29,195 | -25,325 | -22,752 | -19,152 | N/A |
| Other shareholders' equity | -14,883 | -14,883 | -14,883 | -14,883 | 0 |
| TOTAL | $13,352 | $11,962 | $13,025 | $15,344 | $N/A |
| Total Liabilities And Equity | $14,516 | $12,429 | $14,501 | $16,818 | $61 |